Biogen Inc. (BIIB) stock prices updated...
 

Biogen Inc. stock price

Biogen Inc. latest news:


  • 01/25/2018 21:01:50

    Asian shares recoup losses, dollar steady as eyes on Trump

    U.S. stocks are mixed Thursday morning as health care companies including Biogen and Celgene rise, but airlines continue to take steep losses as investors worry about rising costs and the possibility of falling fares.

  • 01/25/2018 13:46:31

    US stocks slip as homebuilders, retailers and airlines skid

    U.S. stocks are mixed Thursday morning as health care companies including Biogen and Celgene rise, but airlines continue to take steep losses as investors worry about rising costs and the possibility of falling fares.

  • 01/25/2018 10:53:40

    Technology companies and drugmakers lead stocks higher

    U.S. stocks are mixed Thursday morning as health care companies including Biogen and Celgene rise, but airlines continue to take steep losses as investors worry about rising costs and the possibility of falling fares.

  • 01/25/2018 04:41:08

    Biogen posts fourth-quarter loss on income tax charge

    U.S. drugmaker Biogen Inc (BIIB) reported a quarterly loss compared with a year-ago profit on Thursday due to a hefty income tax charge for recent changes to the U.S. tax code. The company paid $1.57 billion in income tax in the quarter. Net loss attributable to Biogen was $297.4 million, or $1.40 per share, in the fourth quarter ended Dec. 31. Total revenue rose to $3.31 billion from $2.87 billion.

  • 01/19/2018 05:42:25

    Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors

    Shares of biotech Acorda Therapeutics Inc. surged 20% in premarket trade Friday, after media reports that Biogen Inc. and others are eyeing the company as a possible takeover target. The speculation has been swirling for more than a week. On Thursday, the company offered preliminary guidance for 2017 sales of $542 million, an increase of approximately 10% from 2016. The FactSet consensus is for sales of $568 million. Chief Executive Ron Cohen said he expects 2018 to be a transformative year and for the company to achieve approval and launch its Inbrija investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking carbidopa/levodopa. Shares have gained 21% in the last 12 months, while the S&P 500 has gained about 24%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/08/2018 09:41:17

    Health-care ETF tumbles as biotechnology stocks weigh

    The largest exchange-traded fund to track the health-care sector fell on Monday, dropping as the biggest declining industry of the day by far. The Health Care Select Sector SPDR ETF was down 0.8%, its biggest one-day percentage drop since Dec. 14. The fund is coming off a four-day rally, and it hit a record on Friday. Biotechnology companies were the biggest drags on the sector on Monday. Celgene Corp. fell 3.2% after it agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion. Separately, Biogen Inc. shares fell 3.9% while those for Regeneron Pharmaceuticals was down 3.1%. The iShares Nasdaq Biotechnology ETF fell 0.8% on Monday. Thus far this year, the health-care fund is up 2.3%, compared with the 2.6% rise of the S&P 500 . The S&P was unchanged in Monday trading.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 13:21:48

    Biogen price target raised 20% to $420 at Instinet, citing 'meaningful 2018 for the company'

    Biogen Inc.'s price target was raised 18% to $420 by Instinet on Thursday, citing its expectation of "a meaningful 2018 for the company." The price target increase comes as Biogen shares have slid 3% after a negative analysis was released for one of its Alzheimer's disease drug trials. Instinet analyst Christopher Marai, however, noted high hopes for the company's spinal muscular atrophy therapy Spinraza, agreements Biogen has with companies like Alkermes and Eisai and the company's much-anticipated other Alzheimer's disease drug, aducanumab. "In our view, potentially positive catalysts from BIIB's both widely covered and underappreciated mid- to late-stage pipeline assets (which we do not yet include in our own estimates) will not only be stock-moving but also index-moving, making BIIB 'a must own name.'" Biogen shares have risen 2.6% over the last three months to $323.23, compared with a 7.5% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 09:07:03

    UPDATE: Biogen shares drop 3% on negative update for Alzheimer's disease drug

    Biogen Inc. shares dropped 3% in morning trade Thursday after the company put out a negative update for its Alzheimer's disease drug. An Independent Data Monitoring Committee's 12-month analysis found that the therapy, BAN2401, "did not meet the criteria for success" based on the trial's primary endpoint. The phase 2 trial will continue through 18 months as planned, with a final analysis at the end, which is expected in the second half of next year. Biogen and Eisai Co. have been partners on BAN2401 since 2014, an agreement that included another Alzheimer's disease drug, E2609, which is also still being developed. Last month, the companies expanded the agreement and, as part of it, eliminated milestone payments for BAN2401. BAN2401's phase 2 trial enrolled 856 patients with early Alzheimer's disease. The Independent Data Monitoring Committee's analysis, called a "Bayesian analysis," was used in the hope that "it would enable us to demonstrate clinical success faster than more traditional study designs," said Lynn Kramer, chief clinical and medical officer of the Eisai Neurology Business Group. The companies emphasized that 16 interim analyses that looked at potential for futility did not find it, and that the Bayesian analysis at 12 months found "success was judged at an 80% of higher probability of achieving a Clinically Significant Difference." Despite the company's Thursday share decline, EvercoreISI analyst Umer Raffat said that the trial wasn't well understood and it shouldn't affect company shares much. "Today, all we learned is that the efficacy delta is ~10%)," Raffat said. "Trial continues to mo 18. This is key." Biogen shares have risen nearly 3% over the last three months, compared with a 7.5% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 06:24:15

    Biogen shares drop 4% on negative update for Alzheimer's disease drug

    Biogen Inc. shares dropped 4.1% in premarket trade Thursday after the company put out a negative update for its Alzheimer's disease drug. An Independent Data Monitoring Committee's 12-month analysis found that the therapy, BAN2401, "did not meet the criteria for success" based on the trial's primary endpoint. The phase 2 trial will continue through 18 months as planned, with a final analysis at the end, which is expected in the second half of next year. Biogen and Eisai Co. have been partners on BAN2401 since 2014, an agreement that included another Alzheimer's disease drug, E2609, which is still being developed. Last month, the companies expanded the agreement and, as part of it, eliminated milestone payments for BAN2401. BAN2401's phase 2 trial enrolled 856 patients with early Alzheimer's disease. The Independent Data Monitoring Committee's analysis, called a "Bayesian analysis," was used in the hope that "it would enable us to demonstrate clinical success faster than more traditional study designs," said Lynn Kramer, chief clinical and medical officer of the Eisai Neurology Business Group. The companies emphasized that 16 interim analyses that looked at potential for futility did not find it, and that the Bayesian analysis at 12 months found "success was judged at an 80% of higher probability of achieving a Clinically Significant Difference." Biogen shares have risen 6% over the last three months, compared with a 7% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/19/2017 16:33:19

    BRIEF-Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy

    Biogen Inc(BIIB): * BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY. * BIOGEN WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF THE COLLABORATION. * ‚ÄćIONIS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT AND WILL EARN DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS FROM BIOGEN.

  • 11/27/2017 08:05:35

    Alkermes Could Win Big With New Biogen Partnership


  • More trends:

    Biolase, Inc.BIOL | BioLife Solutions, Inc.BLFS | BioLineRx Ltd.BLRX | BioMarin Pharmaceutical Inc.BMRN | BiondVax Pharmaceuticals Ltd.BVXV | BiondVax Pharmaceuticals Ltd.BVXVW | Bio-Path Holdings, Inc.BPTH | BioScrip, Inc.BIOS | BioShares Biotechnology Clinical Trials FundBBC | BioShares Biotechnology Products FundBBP |